• LAST PRICE
    20.0700
  • TODAY'S CHANGE (%)
    Trending Down-0.5200 (-2.5255%)
  • Bid / Lots
    20.0400/ 1
  • Ask / Lots
    20.4700/ 6
  • Open / Previous Close
    20.1600 / 20.5900
  • Day Range
    Low 19.7500
    High 20.1900
  • 52 Week Range
    Low 9.9250
    High 20.8000
  • Volume
    33,954
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 20.59
TimeVolumeEMBC
09:32 ET1916819.9818
09:33 ET904820.07
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEMBC
Embecta Corp
1.1B
14.8x
-29.08%
United StatesAVNS
Avanos Medical Inc
879.6M
40.7x
---
United StatesBVS
Bioventus Inc
995.8M
-20.1x
---
United StatesOFIX
Orthofix Medical Inc
739.1M
-6.1x
---
United StatesMYGN
Myriad Genetics Inc
1.5B
-12.5x
---
United StatesFIGS
Figs Inc
871.6M
87.1x
---
As of 2024-11-29

Company Information

Embecta Corp. is a global diabetes care company. It is focused on providing solutions to people living with diabetes. It has a portfolio of products, including a range of pen needles, syringes and safety injection devices, which are complemented by its digital application designed to assist people with managing their diabetes. Its pen needles are sterile, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. In addition to pen needles, it sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It has clearance from the FDA for its proprietary disposable insulin delivery system, which is indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D).

Contact Information

Headquarters
300 Kimball Drive, Suite 300PARSIPPANY, NJ, United States NJ 07054
Phone
862-401-0000
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
David Melcher
President, Chief Executive Officer, Director
Devdatt Kurdikar
Chief Financial Officer, Senior Vice President
Jacob Elguicze
Chief Human Resource Officer, Senior Vice President
Jean Casner
Senior Vice President, Chief Technology Officer
Colleen Riley

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.1B
Revenue (TTM)
$1.1B
Shares Outstanding
57.7M
Dividend Yield
2.99%
Annual Dividend Rate
0.6000 USD
Ex-Dividend Date
12-06-24
Pay Date
12-18-24
Beta
---
EPS
$1.35
Book Value
$-12.79
P/E Ratio
14.8x
Price/Sales (TTM)
1.0
Price/Cash Flow (TTM)
9.2x
Operating Margin
14.85%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.